Shenzhen Third People's Hospital

This study tests a new ultra-short treatment (2-3 months) for both drug-sensitive and drug-resistant active tuberculosis (TB). About 610 adults with confirmed TB will receive either the new regimen or standard care. The goal is to see if the shorter treatment works as well or bet…